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 Abstract  
Objective: To systematically review the definitions for “flare” in musculoskeletal conditions, 
the derivation processes, and validation of definitions for the 12 most burdensome 
musculoskeletal conditions.  
Methods: A literature search was conducted in MEDLINE, EMBASE, CINAHL, AMED, 
PsycInfo and Lilacs to identify studies that investigated derivation or validation of a flare 
definition, which we considered as a phrase or group of domains.  
Results: Reports of derivation of flare definitions were identified for 9/12 musculoskeletal 
conditions. Validation of flare definitions was initiated for 4/12. For each condition, different 
derivation and validation methods have been used, with variable levels of consumer 
involvement, and in some cases different groups have worked on the process in parallel. 
Although some flare definitions began simply as “symptom worsening” or “change in 
treatment”, most evolved into multidimensional definitions that include: pain, impact on 
function, joint symptoms, and emotional elements. Frequently initial attempts to create phrase 
to define the term flare evolved into consensus on the breadth of domains involved. 
Validation has compared flare definitions/domains against measures of disease activity, 
clinicians’ diagnosis, response to drug therapy, or a combination.  
Conclusion: This review suggests that greater characterisation and definition of flares in 
musculoskeletal conditions are linked to the inclusion of multiple perspectives, multifaceted 
domains and compound comparators for their validation. Further work is required to optimise 
and test the derived definitions for most musculoskeletal conditions. As some elements are 
disease-specific flare definitions cannot be extrapolated to other conditions. Research 
regarding flare in back pain (most burdensome disease) is limited. 
Keywords: Systematic review, flare, definition, musculoskeletal diseases. 
 1. Introduction  
Musculoskeletal conditions are pervasive and a leading contributor to the global 
burden of disease (1). As many musculoskeletal conditions do not have a cure and become 
lifelong problems, research has focussed on identification of factors that influence the 
progression from acute to chronic conditions, the determinants of the rate of progression of 
the disease, and possible clinical or environmental interventions to halt the progression or to 
reduce the impact of disease. Such consideration depends on a clear understanding of the 
time-course of disease and this relies on clear and unambiguous measures of disease state. A 
major issue is that although symptoms are ongoing, most are characterised by variation or 
fluctuation of symptoms (2) but not all fluctuations are likely to be important (3, 4). For 
several conditions, periods of increased severity of the condition are referred to as a “flare” or 
“flare-up”. Despite the frequent use of this term in research and clinical practice, it is rarely 
clearly defined. It is difficult to be certain whether a flare has the same meaning for different 
conditions. Furthermore, it is unclear whether the terms are used consistently between 
patients, clinicians and researchers, or within these groups.  
For some conditions, such as rheumatoid arthritis (RA), a detailed process has been 
initiated to define and understand flare (5, 6). In these cases, there is advanced understanding 
of patient and clinician interpretations of the term, but the results of each step in the process 
are published in individual papers (e.g. (7, 8)) making it difficult to clarify the overall 
derivation process. For other conditions, parts of the process of derivation of a definition has 
been undertaken, but without overarching coordination of the process. Consequently, the term 
flare is used for multiple purposes such as an outcome measure for clinical trials without an 
explicit definition in most cases. To fully ascertain the current understanding of flare and its 
use in research and clinical practice it was necessary to undertake a systematic review of the 
literature.  
  The overall aim of this systematic review was to comprehensively review the 
definitions that have been derived and validated for the term flare (or flare up) in the 12 most 
burdensome musculoskeletal conditions defined in the Global Burden of Disease Study (9, 
10). Our interest was to gain a comprehensive understanding of flare definitions and domains 
used to define a flare (i.e. worsening of condition; change in treatment). Our specific aims 
were to: (i) document and contrast the definitions or domains used to identify and/or 
characterise flare for the most burdensome musculoskeletal conditions; (ii) assess the 
methods used to derive the definitions or domains; and (iii) review studies that assess the 
validity of definitions or domains of flare. 
 
2. Methods  
2.1 Search strategy 
The methods of this review have been registered with PROSPERO 
(CRD42017056996). We performed a systematic search to identify studies of the key 
musculoskeletal conditions that derived or validated a definition for flare. The key 
musculoskeletal conditions considered were the “major” and “other musculoskeletal 
conditions” determined by Global Burden of Disease (GBD) 2010 Study (10, 11). The “major 
musculoskeletal conditions” are the ones more likely to contribute to the largest proportion of 
musculoskeletal burden based on daily-adjusted life year, i.e., hip and/or knee osteoarthritis 
(OA), low back pain (LBP), rheumatoid arthritis (RA), gout and neck pain. The group of 
“other musculoskeletal disorders” includes systemic lupus erythematosus (SLE), ankylosing 
spondylitis (AS), psoriatic arthritis (PsA), juvenile rheumatoid arthritis (jRA), osteomyelitis, 
fibromyalgia and shoulder pain. We used the search term “flare” combined with each of those 
conditions. A systematic search was conducted in MEDLINE, EMBASE CINAHL, AMED, 
 PsycInfo and Lilacs from the earliest record to February 2017. Searches were conducted in 2 
phases; December 2015 and February 2017. The search terms were adapted for use according 
to database-specific filters. No restriction was applied on study design or language.  
2.2 Study selection 
The results were exported into an EndNote X7.0 database, and duplicates were 
removed. Studies on animals, pregnant women, participants with non-musculoskeletal 
conditions (e.g. cancer) or undergoing surgery were excluded. Two independent reviewers 
(NC and MF) screened all titles and abstracts for potential inclusion. Disagreement was 
resolved by discussion. Full texts of all potentially eligible studies were evaluated for 
inclusion by two reviewers (NC and PH) on the probability that (1) the study defined flare, or 
(2) attempted to validate flare definitions or domains. To capture studies which defined flare, 
we considered the term “defined” to broadly mean both a “phrase” that provided a formal 
definition of the state of flare or a multi-dimensional tool/group of “domains” that could be 
considered to determine whether or not a person was experiencing a flare. Studies including 
mixed patient populations (e.g. non-musculoskeletal conditions and musculoskeletal 
conditions) and patient populations with non-musculoskeletal symptoms (e.g. skin features in 
psoriatic arthritis) were only included if the flare data were separately presented for 
musculoskeletal conditions. Studies written in languages other than English were eligible if a 
translator was available. However, no eligible study was found in non-English languages. 
Studies including induced flares were excluded.  
2.3 Study grouping 
Identified studies were grouped according to the following purposes:  
 GROUP A: Studies that described an experimental study or series of studies that 
aimed to derive a definition or set of domains that characterise a flare; 
  GROUP B: Studies that aimed test the validity of a definition that had been 
proposed/derived for flare or a set of domains that characterise flare. 
2.4 Assessment of study methodological quality 
Study methodological quality was assessed as it pertains to the purpose of our review 
(derivation and validation of the definition for flare) and not the principal design of the study 
(e.g. if data from an RCT was included, the design of the RCT was not evaluated, but the 
process related to derivation of the definition of flare was considered). Different aspects of 
study quality were considered for each study group.  
A major consideration for papers in Group A was that for most conditions, the entire 
process used for derivation of a definition was not contained within a single paper, but 
instead described in a series of papers. The methodological quality was appraised in terms of 
whether the process: 
- Provided clear identification of disease or condition; 
- Considered the perspective of patients, clinicians, and/or researchers (groups were 
recorded); 
- Involved an experimental method to derive the definition (recorded as Delphi; 
qualitative study; consensus meeting; etc.); 
- Considered single or multiple domains to define flare (domains were recorded); 
- Used an experimental method to identify a threshold/cut-off score on a symptom scale 
to characterise a flare (if a cut-off was used this was recorded as “yes” or “arbitrary” 
cut-off); 
- Involved a method to reach consensus for the definition/domains (recorded as yes/no). 
 Methodological quality of studies in Group B was appraised using the following 
criteria: 
 - Clear identification of disease or condition; 
- Representativeness of the sample (i.e. sampled from general community, or sampled 
from a specific group of patients);   
- Clear description of comparator (comparator recorded); 
- Blinding of patients and investigators to assessment of comparators used to validate a 
proposed definition (recorded as yes/no/not applicable);   
- Inclusion of follow-up long enough to allow for flares to be experienced (recorded as 
yes/no/not applicable).  
2. 5 Data extraction  
The data extracted from the studies differed according to group. For all studies we 
recorded the authors, year of publication and condition studied. For studies in Group A we 
recorded the methods used to derive and/or definition or domains, the contributing groups 
(i.e. consumers, clinicians), whether consensus for the definition/domains was achieved, the 
flare definition or identified domains, and measurement tools when appropriate. All 
definitions or groups of domains used to characterise flares included reference to multiple 
features, and the terms used to describe these differed between diseases and research groups. 
To assist with comparison of the definitions/domains, we undertook a thematic analysis and 
allocated each key elements or features of the definitions to one of eleven themes identified 
by consensus of the author group (Table 1). 
For studies in Group B we documented the definition and/or domains of a flare, the 
methods used to test its validity, the groups involved in the validation process, whether the 
definition/domains were validated, and the comparator used for the validation of the 
definition. Data extraction was conducted by independently by reviewers (NC, PH and MF) 
and in case of disagreement, consensus was reached by discussion.  
 2.6 Data presentation 
Data on derivation and validation processes are presented separately for each 
musculoskeletal condition in Table 2 and 3. Study details and assessment of study quality for 
Groups A and B are presented separately in Tables 4 and 5, respectively.  
 
3. Results  
Figure 1 presents the flow chart of the papers screened and included in this review. 
Data are presented according to the two a priori defined categories below.  
3.1 GROUP A: Derivation of a definition or domains of flare.  
 Twenty-eight studies described the derivation of a definition of flare or described the 
identification of domains that characterise a flare. Most considered rheumatologic conditions 
(RA – 9; jRA – 1; Gout – 3; SLE – 6; Juvenile SLE – 1; PsA – 2; OA – 1; AS – 3; 
Fibromyalgia - 1) and one study derived a definition for flare in LBP. Diverse methods have 
been used to develop definitions. All studies clearly identified the condition and included an 
experimental method in their derivation, and the derived definition included at least two 
domains. Forty-six per cent of studies included perspectives from more than one interest 
group. Forty-three per cent involved a method to reach consensus for the definition/domains. 
Only 21% of studies used an experimental method to identify the cut-off on a symptom scale. 
Figure 2 shows the number of conditions that include consideration of each of the themes in 
the definition. The themes of the most commonly included domains were “pain”, “impact on 
function” and “joint symptoms”. Figure 3 shows the number of themes considered for each 
condition. RA, SLE and AS consider the broadest range of themes in their definition. The 
process undertaken, the methodological quality and the resulting definition or domains 
differed between conditions and are presented below separately by condition. 
 Rheumatoid Arthritis (RA) 
The Outcome Measures in Rheumatology (OMERACT) initiative has coordinated 
the derivation of a definition of flare in RA, published across nine papers and one abstract 
(four papers considered validation, see Group B). An initial working definition was derived at 
the 9th OMERACT meeting in 2008 (OMERACT9) and focused on the domains “worsening 
of condition”, “duration”, “symptom intensity”, “change in treatment” (5-7). Analyses of 
focus groups of patients in 5 countries showed that global visual analogue scale (VAS) and 
joint count do not adequately capture flares, suggesting a need for a deeper understanding of 
this experience (12). More recent publications describe a change in strategy from a phrase to 
define flare, to the identification of multiple domains of disease activity (8) that form the 
foundation for a questionnaire to indicate the presence of a flare. The Preliminary Flare 
Questionnaire (PFQ) was developed in 2012 at OMERACT11 (13)  and using core flare 
domains identified in previous meetings. There was lack of consensus between views of 
consumers and clinicians regarding flare domains (e.g. patients, but not, clinicians considered 
fatigue to be important). Validation of the Rheumatoid Arthritis Flare Core Domain Set and 
the Preliminary Flare Questionnaire (PFQ) are discussed in Group B.  
 In parallel, the Strategy of Treatment in Patients with Rheumatoid Arthritis group of 
the French Society of Rheumatology derived a definition of RA flare through the 
development of a self-administered questionnaire (FLARE-RA) containing multiple partially 
distinct domains (14, 15). The FLARE-RA has been validated (see Group B) and a threshold 




 Juvenile Rheumatoid Arthritis (JRA) 
 Brunner et al. (17) used data from a randomised controlled trial of a disease-
modifying drug (Etanercept) to propose and assess candidate flare definitions. Participants in 
the placebo group were assumed to experience flares during the trial duration, whereas those 
in the treatment arm were assumed to be free from flare. The combination of scores from a 
group of clinical variables (core response variables; CRV) was tested using receiver operator 
characteristic (ROC) and positive and negative predictive values for group allocation. Three 
proposed definitions performed adequately for accurate identification of presence of a flare. 
These related to the domain of “worsening of condition” as assessed by clinical tests, in 
combination with results from questionnaires and laboratory tests. 
Gout  
 Although flare is frequently identified as an important feature of chronic gout (18-20) 
there have be few attempts to define or identify the domains that characterise a gout flare. A 
consensus exercise involving two Delphi surveys and a cognitive mapping process involving 
patients, clinicians and experts identified nine key elements of a gout flare definition (21). 
The European League Against Rheumatism (EULAR) evaluated the utility of these elements 
of gout flare to develop a patient-centred definition. At eight international sites, 210 patients 
were assessed by nine experienced rheumatologists. The physician’s determination of the 
presence or absence of gout flare was the comparator. Logistic regression and classification 
and regression tree (CART) were used to identify the best predictors of a flare. Patient-
reported flare, presence of any warm joints or swollen joints, and joint pain at rest with a 
score >3 were strongly associated with the comparator physician’s determination of presence 
of a gout flare (22). 
  A novel approach to flare definition was attempted by MacFarlane et al (23). Using 
computerised medical records, they aimed to identify claims-based algorithms that could to 
identify gout flares and assessed against physician documentation of gout flare. Claims-based 
algorithms did not accurately identify gout flares.  
Systemic Lupus Erythematosus (SLE)  
 Flares have been largely recognised as an important feature of the disease pattern in 
SLE and used to represent “worsening of disease activity” (24). Eight instruments in different 
versions and modifications (e.g. British Isles Lupus Assessment Group 2004 index – BILAG, 
Systemic Lupus Erythematosus Disease Activity Index – SLEDAI, The Safety of Estrogen in 
Lupus Erythematosus National Assessment – SELENA, Lupus Activity Index - LAI) have 
been proposed. As SLE involves many systems other than the musculoskeletal system, most 
definitions include a multi-system perspective (e.g. seizure, cardiorespiratory symptoms, etc). 
Most research has used a change in score on these disease activity instruments to quantify 
and characterize flare (24). Cut-offs for a flare were established for BILAG, SLEDAI, 
SELENA SLEDAI and LAI (25-29).  
 In 2006, The Lupus Foundation of America (LFA) convened an International 
Consensus Panel “Definition and Validation of Lupus Flares” to evaluate needs in defining 
and measuring SLE flares. Two web-based Delphi surveys of physicians, a second consensus 
conference (which included patients), and a third Delphi survey were undertaken to reach 
final consensus (30). The definition of flare was broadened to include more domains as a 
result of this process. A separate study achieved a consensus for a flare definition and 
candidate flare criteria in Juvenile Systemic Lupus Erythematosus (jSLE) (31). Work to 
assess validity of definitions and instruments has been done (see Group B).  
 
 Psoriatic arthritis (PsA)   
          Moverley et al. (32) aimed to define flare in PsA. Interview data from patients were 
analysed thematically. Flares were defined as a collection of interacting “physical”, 
“psychological” and “emotional” symptoms defined by several domains. Furthering this 
work, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 
conducted two Delphi surveys and a face-to-face discussion to define flare and its domains 
towards the development of a questionnaire to identify flare in PsA (33). Development of the 
questionnaire is ongoing.   
Osteoarthritis (OA) 
 Marty et al. (34) conducted two observational cross-sectional studies to derive and 
validate a diagnostic score for OA flare based on clinical and radiological features. Initial 
data were obtained from general practitioners and used to develop a diagnostic score for 
patients seeking primary care. To build the instrument and derive cut-off scores, patients with 
stable condition and those experiencing a flare were recruited. Patients’ demographics and 
clinical characteristics, including pain severity, functional impairment and treatment, were 
included in logistic regression models to identify factors independently associated with flare. 
A score ≥7 was identified when each factor was given a weight for the odds of not having a 
flare. This score was validated using a rheumatologist database (see Group B). 
Ankylosing Spondylitis (AS) 
 Brophy et al. (35) examined patients’ perceptions of the important domains for flare 
definition in AS. In twenty group meetings of 7-12 participants, 214 patients were asked 
questions regarding flare and its triggers, duration, sequelae and frequency. A consensus 
definition of flare was obtained by each group. Data revealed two forms of flares (“localised 
 to one area” and “throughout the body”). Both were marked by highly painful symptoms 
triggered by stress in the majority of cases.  
 The Assessment of Spondyloarthritis (ASAS) group conducted a systematic review of 
flare definitions and vignette exercises to develop a consensus definition of flare. Diverse 
flare definitions were found and 12 preliminary draft flare definitions were proposed for 
further validation (36).  
 Godfrin-Valnet et al. (37) aimed to derive a definition of flare based on disease 
activity indices. ROC curves were used to identify thresholds for optimum sensitivity and 
specificity to detect flares reported by patients and physicians. Specificity was strong, but 
sensitivity was only moderate and agreement between patients and physicians was only 
moderate (Kappa 0.68). 
Fibromyalgia 
 Vincent et al. (38) identified domains of flares in patients with fibromyalgia using a 
qualitative survey. Content analysis identified three main content areas and key themes 
within each of these content areas: causes of flares (stress, overdoing, poor sleep and weather 
changes), flare symptoms (flu-like symptoms, pain, fatigue, other symptoms) and dealing 
with flares (treatments, rest, avoid everything and wait it out). No definition was derived or 
validation attempted. 
Low Back Pain  
One study has proposed a definition of flare for LBP (39). This qualitative study 
originally aimed to examine how individuals with a history of LBP describe events that could 
be conceptualized as “recurrent episodes”. The results suggested people with LBP believe 
they live with a baseline level of their condition, and in their opinion, a recurrent episode is 
better represented as a period worsening of their ongoing condition, recognised as “flare-ups” 
 or “attacks”. According to participants’ views, flares were not only characterised by pain, but 
also moderate activity limitations, participation restrictions, need for activities to help 
manage their pain, and fear of worsening of their condition. “Flares” tended to be viewed as 
manageable whereas “attacks” were considered more severe, involving more pain and “the 
inability to do anything”. 
3.2 GROUP B: Validation of a flare definition 
 Twenty-three studies undertook a process to validate the definition or domains of flare 
as summarised in Table 5. All considered rheumatologic conditions (RA – 14; Gout – 1; SLE 
– 6; OA – 2). Only 56% of studies recruited participants from the general community. Others 
used specific groups (30%; e.g. participants receiving a specific treatment) or did not provide 
this information (14%). Of studies aiming to validate a flare definition, 65% (n= 15) were 
observational studies and 21% (n=5) were randomised clinical trials. One study was a 
multicentre trial and one study aimed to validate the flare definition in different languages. 
Disease activity measures were used as the comparator in 65% (n=15) of studies. From those, 
27% (n= 4) used disease activity measures combined with other instruments to measure 
function, health-related quality of life and/or outcome measures of other domains, and 53% 
(n= 8) combined disease activity measures with either patients’ and/or clinicians’ 
perspectives. Eighteen per cent (n=4) relied solely on clinicians’ perspectives, and 9% (n=2) 
considered only patients’ perspectives. In 73% of studies patients and/or investigators were 
blinded to results of the comparator in the validation process. Results are presented below 




 Rheumatoid Arthritis 
 Responsiveness of the OMERACT preliminary flare questions (PFQ) to changes in 
flare status determined by rheumatologist, patient self-reported state or one of the two 
proposed DAS28-based criteria was tested. Scores in each PFQ domain changed significantly 
for those experiencing flares and remained unchanged for whose flare status was unchanged. 
DAS28 criteria (Ritchie Articular Index, number of swollen joints, erythrocyte sedimentation 
rate (ESR) and a general health assessment scored on a VAS (40)) were insensitive to change 
(41). Construct and discriminatory validity of the PFQ were examined in a RCT of TNF-
blocking drugs vs. usual care. A statistically significant change in scores (compared to 
baseline) of all PFQ items was found only in patients experiencing a flare defined by DAS28 
(42). Breakout group discussions at OMERACT 2014 identified issues regarding assessment 
of the domains stiffness and self-management. Refinement of RA flare measurement 
continues (43).  Convergent and divergent construct validity of the individual domains of flare 
identified by OMERACT has been assessed (44) from their change over time (3 and 6 
months) and compared against flare defined by DAS28 and three flare working definitions:  
worsening of symptoms (self-reported), change in treatment (observed) and the combination 
of these two domains. Flare defined as ‘self-reported worsening of symptoms’ yielded higher 
standardised mean differences than “change in treatment”.  
 Barlett et al. showed discriminant validity of PFQ between patients with and with 
self-reported flare, and convergent validity between PFQ and validated RA measures (45). 
Bykerk and colleagues showed modest agreement between patients and rheumatologists in 
identifying a flare and the concordance of clinical and patient-reported outcomes (PRO) with 
flare status; patients identifying more swollen and tender joints. PRO significantly 
discriminated between patients reporting flare and those who did not (46) 
   Validity of the FLARE instrument has been assessed in six studies (47-52). First, a 
prospective trial of the FLARE Self-report questionnaire showed it is a valid and valuable 
instrument to detect RA flare between visits to the physician (50). Second, an observational 
study showed good correlation between detection of past flares using the FLARE-RA 
questionnaire and the Routine Assessment of Patient Index Data (RAPID) questionnaire (47). 
Third, comparison of the questionnaire data against clinical and laboratory measures of 
disease activity and severity revealed a high correlation with the all measures except for the 
Physician Clinical Assessment (PCA) (48). Fourth, validity and reliability of the Danish 
version of the Flare Instrument (FI) was found to be excellent against DAS28 (intra class 
correlation coefficient >0.95) (52). Fifth, assessment of the criterion and concurrent validity 
of the Danish version of the FI against DAS28-CRP found good to moderate diagnostic 
properties (49). Sixth, FI was translated into Spanish and a cut-off value ≤50.5 was found to 
determine the presence of a disease flare with high sensitivity and specificity (>60), which 
was more strongly correlated with patient’s opinion and treatment change between visits than 
with physician’s opinion and disease activity scores (51). 
 Two studies validated the definition of flare based on DAS28. Dougados et al. used 
RCT data to compare DAS28 against the investigators’ opinion. DAS 28 was sensitive (88-
100%) but not specific (57-65%) to identification of a flare (53). Portier et al. (54) showed 
difference in conceptualisation of flare between patients and DAS28 (which was considered 
to reflect the physician’s opinion; Kappa 0.44). Patient-reported flares emphasised physical 
and mental domains, but joint pain was rarely indicated as the only flare symptom (16.8% of 




 Teoh et al. (55) assessed the validity of six methods to report flare against gout 
disease activity measures [patient and physician global assessments, joint counts and C-
reactive protein (CRP)]. All methods correlated well with measures of gout disease activity, 
except “time to first flare”.     
Systemic Lupus Erythematosus (SLE) 
 Patients with SLE were included in a study examining the intra- and inter-rater 
reliability of the Physician Global Assessment (PGA), the SLEDAI and SELENA. Whereas 
the PGA and the SLEDAI showed high intra- (>0.87) and inter-rater (>0.75) reliability, the 
SELENA tool showed only moderate reliability (<0.52). Agreement among the three 
instruments was poor (56). 
            Data from five visits of 230 SLE patients were assessed to determine correlations 
between SLEDAI scores and clinicians’ views of disease activity levels. A flare was 
considered to have occurred if new or increased therapy was prescribed for active disease, or 
if the physician’s notes indicated an expression of concern or use of the term flare. An 
increase on SLEDAI over 3 points agreed with the clinical determination of flare (26).  
 Isenberg et al. (57) compared flare definitions derived from the BILAG 2004 and the 
SFI against the PGA based on the Lupus Foundation of America (LFA) flare definition. The 
BILAG 2004 based definition of flares was more consistently associated with the opinions of 
physicians. Petri et al. (58) compared the revised SELENA flare index (rSFI) and its original 
version (SFI) to the BILAG index, which discriminates between severe, moderate and mild 
flares in patients with SLE. The results suggest higher agreement between the BILAG and the 
rSFI than its original version (SFI). The SELENA-SLEDAI flare index (cSFI) was compared 
to a version without a criteria related to medication and with clinical judgment. Results 
 indicate that the addition of medication dose did not improve the relationship between cSFI 
and clinically defined flare (59). Brunner et al. (31) identified patients with flare or stable 
jSLE using their candidate flare criteria. PGA, disease activity measure, anti-dsDNA, 
creatinine ratio and parental global assessment of well-being were found to adequately 
capture jSLE global flares diagnosed by rheumatologists. 
Osteoarthritis 
 Using a qualitative methodology Murphy et al. (60) showed that the definition of 
osteoarthritis flare based on “inadequate pain relief brought on by too much activity” did not 
match patients’ perspectives and opinions. Marty et al. (34) revealed good validity for Knee 
Osteoarthritis Flare-Ups Score (KOFUS) and cut-off score to define flare when using the 
rheumatologist diagnosis as a standard. 
4. Discussion  
 This systematic review identified that a process towards a flare definition has been 
initiated for nine of the 12 most burdensome musculoskeletal conditions. Diverse methods 
have been used to derive and/or validate a definition for flare or its domains in 
musculoskeletal conditions with varying degrees of patient consultation. A process to validate 
the definitions/domains has been initiated for only four. For some burdensome diseases (e.g. 
shoulder pain, neck pain and osteomyelitis), no process of definition derivation has been 
initiated. Research in the field of LBP – the most burdensome disease globally in terms of 
years lived with disability (9) – is limited to one qualitative study that indicates people with 
LBP consider their condition to be ongoing and characterised by “flares” rather than discrete 
episodes of pain, even if they have pain-free periods. 
 
 
 4.1 Themes in flare definitions 
 Although several processes to define flare began with an objective to derive a simple 
definition for flare there is consensus that definition requires consideration of multiple 
domains. Pain, impact on function and joint symptoms were the most common themes 
(included in 77% of the definitions). The themes emotional symptoms (55%) and fatigue 
(55%) were frequently considered. Some definitions were uni-dimensional and focused on 
the biomedical features of objective clinical measures (e.g. (5-7)) whereas others were 
multidimensional and considered a biopsychosocial profile with inclusion of objectively 
measured and self-reported aspects of the experience of a flare (e.g. (8, 13)). The methods 
used and groups included in the derivation processes had an impact on the flare definitions. 
As might be expected, when clinicians’ perspectives were emphasised, clinical signs (e.g. 
Gout (19) - pain and warm, swollen and stiff joints) were highlighted. Definitions derived 
using clinicians’ perspectives also tended to exclude “fatigue” as an important component of 
flare, but included “change in treatment” or “pain” as main components (e.g. RA (13, 44)). In 
contrast, consideration of patient perspectives revealed flare as a complex experience and the 
domain “change in treatment” did not adequately identify flares (42, 44, 59). Further, when 
patients’ views were considered, the definitions tended to include a broader biopsychosocial 
conceptualisation of flare, including features such as changes in function, emotional aspects 
and fatigue (e.g. RA, SLE, fibromyalgia and osteoarthritis patients (13, 30, 38, 60)). Not 
surprisingly there is only moderate agreement between patients and physicians regarding 
when they have a flare (37, 41, 54). Regardless of the group considered, there is consensus 
that a definition for flare must consider more than an increase in pain. HCPs’, researchers’ 
and patients’ perspectives appear to be complementary and essential for a deeper 
understanding of flares. This finding agrees with current literature which argues that the use 
of patient reported outcome measures narrows the gap between clinicians’ and patients’ 
 views of health states, leading to better communication and decision making (61). Automated 
methods to identify flare from patient records have not been successful (23, 55) 
4.2 Validation of flare definitions 
 Using a variety of approaches to assess the validity of the proposed 
definitions/domains, most studies showed good relationship with other measures/features of 
flare. Studies relied mainly on comparison against existing clinical measures of disease 
activity and only a few include measures of non-biomedical domains (e.g. fatigue, health 
related quality of life). Thus, in most cases the flare definitions/domains under investigation 
were more multidimensional than the comparators used to validate them. This questions 
whether the studies provide an optimal estimate of validity. Despite this limitation, available 
data show that flare definitions/domains agree with disease activity measures, and correspond 
to patient’s and physician’s perspectives, with some exceptions (48, 60)). An issue to 
consider is that many validation studies relied on participants that are unlikely to represent 
the general population (e.g. limited to a subset of patients receiving a specific intervention).  
4.3 Comparison between conditions 
Among musculoskeletal conditions included in this review, the RA OMERACT 
process towards a flare definition has been the most comprehensive with in-depth 
consideration of all stakeholders’ opinions. Patients have been included in all steps towards a 
flare definition, including perspectives of patients from international sites. Recognising flare 
as a multidimensional construct, the RA OMERACT group were the first to change their 
strategy from derivation of a single phrase to describe the state, to an approach that aims to 
identify the multiple domains that might characterise a flare (6). The established flare 
domains are being used to build a questionnaire to identify flare based on defined thresholds 
(41).  
 No domain was universally used to define a flare among the musculoskeletal 
conditions investigated. The heterogeneity among musculoskeletal conditions, the use of 
different methods and different degrees of maturity of the derivation process to define flare 
makes it difficult to directly compare definitions applied to different conditions. However, 
some differences between flare definitions/domains are clear. First, the complex pathology of 
SLE which affects multiple systems in addition to musculoskeletal issues is reflected in the 
high number and nature of the domains involved in its flare definition. Second, several 
diseases have hallmark signs that are included – e.g. number of swollen/painful joints in RA 
and Gout. Others are less easily identified through clinical signs and do not contain disease-
specific domains - e.g. Fibromyalgia and LBP. 
It might be reasonable to expect that flare in an ongoing systemic condition such as 
RA could be different to conditions commonly characterised by repeated episodes such as 
LBP. However, this was not the case. Contrary to the expectation of Young et al. (39), 
patients with LBP considered their condition to be ongoing (despite periods without pain) and 
characterised by flares rather than discrete symptom episodes.  
Flare in some of the major musculoskeletal conditions have not yet been considered. 
As flare is not considered identically for all conditions, it is not possible to extrapolate from 
existing definitions to conditions where the process has not been commenced and the process 
must be undertaken individually if flare is to be considered an accurate and relevant aspect of 
a condition. It is likely that similar to the other investigated musculoskeletal conditions, flares 
of neck pain, shoulder pain and osteomyelitis may be a multidimensional concept, and 
aspects of the disease and its impact, other than pain, should be considered. 
 
 
 4.4 Flare vs. other types of symptom fluctuation 
This systematic review suggests the concept of flare differs from other definitions 
commonly used to describe fluctuations of symptoms (e.g. episode, recurrence), as those are 
commonly defined only taking into consideration duration, intensity of symptoms, and when 
the period of symptoms is preceded by a period without symptoms (e.g. LBP recurrence 
(62)). It is likely that risk factors for flares will be different to those associated with a new 
episode of a condition, and these need to be studied separately. 
4.5 Conclusion 
The findings of this systematic review indicate that flare is a multifaceted experience 
that differs in some respects between conditions. There is consensus that definitions of flare 
require consideration of aspects in addition to pain and symptom intensity, but the breadth of 
features of the experience of flare was greater when perspectives of patients were considered. 
Whether flare can be adequately defined using a phrase or requires detailed consideration of 
multiple domains has not been established and may vary between conditions. It is clear that 
flare cannot be distilled to a simple consideration of whether treatment has changed. 
Validation of definitions remains challenging as most measures used for comparison are more 
restricted in their consideration of flare that the definitions and domains that have been 
derived. Further work is required to optimise and test the derived definitions for most 
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Worsening of disease activity/condition, a cluster of symptoms, new or 
worse signs, increase in disease activity. 
Change in treatment 
(CT) 
(Re)initiation or change (increase, change medication) of therapy, 
increase/add self-management. 
Pain (P) Pain intensity, nocturnal pain/awakenings, DAS28. 
Symptom intensity 
(SI) 
Intensity of symptoms, overwhelming physical symptoms. 
Duration (D) Duration, persistent, time to maximum pain level, time to complete 
resolution of pain, duration varying between days and weeks. 
Impact on function 
(IF) 
Function, participation, physical symptoms, changes in daily activity, 
Childhood Health Assessment Questionnaire. 
Joint symptoms (JS) Number of joints with active arthritis/limited range of motion, 
swollen/warm/tender/stiff/painful joints, DAS28. 
Patient self-reported 
state (PS) 
Self-reported flare, patient global assessment, parent and patient global 
assessment of overall well-being. 
Biomarkers (B) Laboratory tests (e.g. ESR, CRP levels, acute phase marker). 
Emotional 
symptoms (ES) 
Emotional/psychological changes/symptoms/consequences), health related 
quality of life, coping, anger, depression, withdrawn. 
Physician 
assessment (PA) 
Physician global assessment. 
Fatigue (F) Physical fatigue, emotional fatigue. 
Other (O) Frequent, rare and random, manageable, flu-like symptoms/fever, muscle 
spasm, cramp, burning or tightness in the muscle, sweats, loss of appetite, 
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DAS44/DAS28 – Disease Activity Score. The numbers 44 and 28 refers to the 44/28 joints that are examined in this instrument; VAS - 
Visual Analogue Scale; EGA - Evaluator Global Assessment; HCP – Health Care Professionals; RCT – Randomized controlled trial; CRV – 
Core Response Variables; PGA – Physician’s Global Assessment; ESR – Erythrocyte Sedimentation Rate; ICD-9 – International 
Classification of Disease-9; NSAID - Nonsteroidal Anti-Inflammatory Drugs; CPT – Current Procedural Terminology; J code - Healthcare 
Common Procedure Coding System (HCPCS) codes for injection of drugs; LAI – Lupus Activity Index; SLEDAI - Systemic Lupus 
Erythematosus Disease Activity Index; SELENA Flare tool - Safety of Estrogens in Lupus Erythematosus National Assessment  Flare tool; 
CNS-SLE – Central Nervous System-Systemic Lupus Erythematosus; PLT - Platelet; HB - Haemoglobin; BILAG - British Isles Lupus 
Assessment Group 2004 index; KOFUS – Knee Osteoarthritis Flare-ups Score; ASDAS - Ankylosing Spondylitis Disease Activity Score; 
 ASDAS-CRP – Ankylosing Spondylitis Disease Activity Score-C-reactive protein; ASDAS-ESR - Ankylosing Spondylitis Disease Activity 
Score-Erythrocyte Sedimentation Rate; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index.  
* See Table 1 for abbreviations for Themes 
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except time to 
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active disease - 
increase/decreas
e of SLEDAI up 
to 3; remission - 
SLEDAI = 0 
 














N=16 Cohort Study: 
Assessment of 
internal 
reliability of 3 
instruments 
(ICC with 95% 
CI) 
BILAG 2004, 





















(95% CI) at 
0.54 (0.32 to 
0.78)] than 
SELENA flare 
[at 0.21 (0.08 


















Trial: rSFI vs. 
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were compared. 
Descriptive 






























the severity of 
a clinical flare 
 





















A flare is a 
measurable 
worsening of juvenile 
SLE disease activity 
in at least one organ 
system, involving 
new or worse signs of 
disease that may be 
accompanied by new 
or worse SLE 
symptoms. 
Depending on the 
severity of the flare, 
more intensive 
therapy may be 
required 
Rate change in 
































Inadequate pain relief 
for an episode of 
intense pain that is 
usually brought on by 
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PFQ – Preliminary Flare Questionnaire; DAS/DAS28 – Disease Activity Score. The number 28 refers to the 28 joints that are examined in 
this instrument; DAS28-CRP - A composite score including the patient’s global assessment, report of physical functioning (HAQ), and the 
measurement of an acute phase reactant (CRP), together with a physician-based count of tender and swollen joints; N/A – Not applicable; 
DMARDS – Disease Modifying Anti-rheumatic Drugs; 28-SJC – 28-Swollen Joint Counts; 28-TJC – 28-Tender Joint Counts; ESR – 
Erythrocyte Sedimentation Rate; CRP – C-reactive protein; VAS - Visual Analogue Scale; PGA1 - Patient Global Assessment; SF36 – 36-
item short form survey (SF36 Bodily pain, SF36 Physical functioning, SF36 Social functioning, SF36 Role limitations physical, SF36 Role 
limitations emotional, SF36 Mental health); MHAQ – Modified Health Assessment Questionnaire; BASDAI – Bath Ankylosing Spondylitis 
Disease Activity Index; HAQ - Health Assessment Questionnaire; SF12 – Short Form 12 Questionnaire; ACR criteria – American College 
of Rheumatology criteria; RAID - Rheumatoid Arthritis Impact of Disease; RAPID - Routine Assessment of Patient Index Data; RAPID3 – 
Routine Assessment of Patient Index Data 3; BRAF - Bristol Rheumatoid Arthritis Fatigue; ICC – Intra-class Correlation Coefficients; IL6 - 
Interleukin-6; ROC – Receiver Operating Characteristic; PPV – Positive Predictive Value; NPV – Negative Predictive Value; PCA - 
Physician Clinical Assessment; SEM – Standard Error of the Measurement; Work productivity and Activity Impairment Questionnaire – 
WPAI; LOA – Limits of Agreement; MDC – Minimally Detectable Change; PGA2 – Physician’s Global Assessment; LFA – Lupus 
Foundation of America; SLEDAI - Systemic Lupus Erythematosus Disease Activity Index; SELENA Flare tool - Safety of Estrogens in 
Lupus Erythematosus National Assessment  Flare tool; BILAG - British Isles Lupus Assessment Group 2004 index; SFI - Selena Flare 
Index; rSFI – Revised Selena Flare Index; eSFI – Experimental Selena Flare Index; cSFI – Classic Selena Flare Index; jSLE – Juvenile 
Systemic Lupus Erythematosus; OA – Osteoarthritis; KOFUS – Knee Osteoarthritis Flare-ups Score.  
* Flare self-reported questionnaire, Flare-RA questionnaire, Flare assessment in RA (FLARE) questionnaire and Flare Instrument (FI): all 
refer to the same instrument. 
 
  


























Rheumatoid Arthritis (RA) 














Yes N/A N/A N/A Q, F, D, 













Yes Yes Yes Yes CM No Yes 









Yes Yes Yes No Q No Yes 




Yes Yes Yes No P Yes No 

















Yes No Yes No C No No 
























Yes Yes Yes Yes CP No Yes 
Study Clear Perspecti Perspecti Perspecti Derivat Used a Consen
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sus 
Process 





Yes No Yes No D No Yes 















Yes Yes Yes No OCS Yes No 





Yes Yes No No GM No No 
















Yes Yes No No Q No No 




Yes Yes No No Q No No 
LR – Literature review; F – Focus group; CM – Consensus Meeting; W – Workshop;  Q – Qualitative Study; RCT – Randomised Controlled 
Trial; D – Delphi; B – Breakout groups; P – Prospective Study; C – Cohort study; CP – Consensus Panel; OCS – Observational cross-
sectional study; GM – Group meetings; V – Vignette exercise; L – Longitudinal study. 



























Rheumatoid Arthritis (RA)  




Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 




Yes RCT using TNF-blockers or 
usual care 





Yes N/A N/A N/A N/A 
Lie et al.
44 
Yes 5 Norwegian rheumatology 
departments using DMARDS 
and/or biologics.  





Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 




Yes Patients from a Canadian 
early ArThritis CoHort 
(Observational Study) 
Yes Yes Yes 





Yes 138 patients >18 years with 
RA diagnosis (1987 ACR 
and/or 2010 ACR/EULAR 
criteria), disease evolving for 
≥6 months, treatment with 
synthetic or biologic 
DMARDS for ≥2 months and 
stable symptomatic treatment 
for ≥2months  




Yes Patients from 13 treated with 
stable doses of DMARDs 




Yes 160 RA Patients - 
population-based cohort 
(1987 ACR criteria) 
Yes Yes Yes 
de Thurah et 
al.
49 
Yes Outpatient clinic treated with 
DMARDs 




Yes Out-patient clinic in 
Denmark 




Yes ≥18 years, RA 
(ACR/EULAR 2010 criteria) 
Yes Yes Yes 
 





















Yes 553 patients, 118 
centres in 19 
countries (Europe, 
America and Asia) 
using tocilizumab + 
methotrexate or 
placebo 




Yes ≥18 years, RA (ACR 
1987 criteria) 




Yes 120 gout patients Yes Yes Yes 





Yes Randomly selected 
from rheumatology 
outpatient clinics 
(UCLA – Los 
Angeles) 




Yes Patients from Uni. 
Toronto Lupus Clinic 





Yes Limited to patients 
from 2 lupus clinics 
seeking care during 
the previous 3 weeks 
Yes Yes No 
Petri et al.
58 
Yes Limited to patients 
from a RCT 
conducted in USA, 
Latin America and 
Europe using 
rontalizumab 




Yes Limited to SLE 
patients - Oklahoma 
Lupus Cohort Study, 
(1997 modified ACR 
criteria) 




Yes Limited to patients 
≤16 years from 7 US 
paediatric 
rheumatology clinics  





Yes Limited to  moderate 
to severe pain from 
the Uni. Michigan 
Clinics 




Yes Clinical and 
radiological criteria 
for knee osteoarthritis 
(ACR) 
No Yes No 
RCT – Randomized Controlled Trial; DMARDS – Disease Modifying Anti-rheumatic Drugs; ACR– American College of Rheumatology; 






















































































 Additional records 
identified through 
other sources  
(n = 2) 
Records after duplicates removed  
(n = 3,989) 
Records screened  
(n = 3,989) 
Records excluded  
(n = 2,449) 
‘Flare’ not defined (n=1993) 
Pregnant women (n=320) 
Animal studies (n=53) 
Participants undergoing surgery (n=46) 
Induced flares (n=19) 
Non-musculoskeletal conditions (n=18) 
Full-text articles assessed 
for eligibility  
(n = 1,540) 
Full-text articles excluded  
(n = 1,489) 
“Flare” not defined (n=829) 
flare definition/domains not derived or 
validated (n=397) 
Study did not derive or validate a “flare” 
definition (n= 263) 
Studies included in 
qualitative synthesis  
(n = 51) 
Studies reporting 
derivation of flare 
definition 
(n = 28) 
Studies reporting 
validation of flare 
definition 
(n = 23) 
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